Genetic Engineering & Biotechnology News’ Post

High-Throughput Cell-Line Development U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, hopes the new improvements are a move towards reducing cell-line development timescales to help tackle future pandemics. https://hubs.ly/Q02Km1qj0

Cell line development can be a bottleneck in drug discovery because it can be challenging and time consuming. High-throughput cell line development is an impressive achievement speeding up the drug discovery processes. 

Happy to share our review on recent findings of Immune responses leading to severe #dengue. What we know and what we don't. Sadly, there is so much we don't know that hinders biomarkers discovery, development of more effective vaccines and treatment. #ntds #vaccines #infectiousdisease #climate change #biomarkers Allergy, Immunology and Cell Biology Unit University of Sri Jayewardenepura https://lnkd.in/gSuBmrSB

Our latest publication on the co-circulation of multiple dengue virus genotypes! Our findings emphasize the critical need for continuous surveillance to detect mutations that evade diagnostics and affect virulence. Let's stay vigilant! Allergy, Immunology and Cell Biology Unit

New Hope for AFM: NIH Tests Experimental Monoclonal Antibody TOPICS:AntibodiesInfectionNational Institute Of Allergy And Infectious DiseasesNational Institutes Of HealthVirus By NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES JULY 7, 2024 "[...] Monitoring and Historical Context of EV-D68 Clinical Trial NCT06444048 will enroll 36 healthy volunteers ages 18 to 49. Six will receive a placebo (control group) and 30—in groups of 10—will receive either a 3, 10, or 30 mg/kg dose of EV68-228-N intravenously. As part of the safety evaluation, scientists will monitor the first two study participants in each group receiving the experimental treatment for at least 72 hours before others receive the infusion. Researchers will then monitor and evaluate study participants during nine subsequent in-person examinations over the next 120 days.[...]"

https://lnkd.in/dKVnH7Rz SEVERE DENGUE LESSONS LEARNED- Vaccines Beat The extent and duration of viraemia often appears to be associated with clinical disease severity but with some variability. However, there also appear to be significant differences in the kinetics of viraemia and nonstructural protein 1 (NS1) antigenemia and pathogenicity between different serotypes and genotypes of the DENV. These differences may have significant implications for development of treatments and in inducing robust immunity through dengue vaccines. Although generally higher levels of neutralizing antibodies are thought to protect against infection and severe disease, there have been exceptions and the specificity, breadth and functionality of the antibody responses are likely to be important.

It has been four years since the start of the COVID-19 pandemic. SARS-CoV-2 has yet to be eradicated and new variants are continuously emerging. Despite the extensive immunization programs, breakthrough infections (infection after vaccination) by new variants are common. New research suggests that human immune responses are also changing in order to combat the never-ending emergence of new SARS-CoV-2 variants. Specifically, it has been discovered the immune system that encountered breakthrough infection by the omicron variant acquires enhanced immunity against future versions of the omicron. The study is published in Science Immunology. https://lnkd.in/gSUQb7aM

Sharing our paper on two DENV-3 genotypes (I and III) co-circulating and causing a large #dengue outbreak in #srilanka in 2023. We observed a discrepancy between dengue NS1 antigen test and molecular diagnostics, with the emergence of (DENV) serotype 3 in Sri Lanka and sought to understand the cause for the high failure rates of molecular diagnostics. DENV-3 genotype III was detected by the modified CDC DENV-3 primers whereas, genotype I evaded detection due to key mutations at forward and reverse primer binding sites. Furthermore, our Sri Lankan DENV-3 strains demonstrated a high root to tip ratio, compared to the previous DENV-3 sequences, indicating a high mutation rate during the points of sampling (year 2017 to 2023). Dinuka Ariyaratne Tibutius Thanesh Pramanayagam Jayadas Bhagya Senadheera Heshan Kuruppu Diyanath Ranasinghe Farha Bary Chandima Jeewandara, MBBS, MSc (Allergy), PhD (Immunology) Allergy, Immunology and Cell Biology Unit #diagnostics #PCR #sequencing #nanopore #surviellance #NS1 #RDTs

https://lnkd.in/gwSd9_MF   Article title: Preparation and Application of two Monoclonal Antibodies against Canine Parvovirus Vaccine and Field Strains   Author(s): Liying Hao, Ying Wang, Chenyu Bai, Yudan Jin, Dingding Zheng, Lingyan Chen, Xiangdong Li, Junhua Deng and Kegong Tian*   Journal: Journal of Vaccines and Immunology   Journal ISSN: 2640-7590   Abstract: Background: Canine parvovirus (CPV) emerged in 1970s as a highly infectious disease. CPV modified live vaccines have been widely used to control the disease. It is urgent to develop specific monoclonal antibodies to differentiate field virus from vaccine virus in vaccinated dogs.   Methods: In this study, female BALB/C mice were immunized with a commercial CPV vaccine strain. Two monoclonal antibodies (MAbs) 10H4 and 10B11 were made by hybridoma technique, and screened by hemagglutination inhibition (HI) assay.   Results: MAb 10H4 reacted with both CPV field and vaccine strains, and MAb 10B11 only recognized field but not vaccine strains by the results of HI, indirect immunofluorescence (IFA), and virus neutralization tests.   Conclusion: Therefore, these two MAbs may work as useful tools to study the CPV pathogenic mechanisms and to develop diagnostic reagents.   #CanineParvovirusType2 #MonoclonalAntibody #Neutralization #ImmunologyMechanisms #AnimalModelsForImmunologicDiseases #ViralImmunology #Peertechz #Immunopathogenesis #VaccineDevelopmentAndEfficacyEvaluation #ImmuneResponsesToVaccines #VaccineTechnology #VaccineVectors #AdjuvantsAndImmunomodulators #ProphylacticVaccines #TherapeuticVaccines #AIDSVaccines #GeneVaccines #VaccinesInBioterrorism #RegulatoryAffairs #CommercialUtilization #Policy #Safety #Epidemiology #AntigenProcessingAndPresentation #DesignProductionAndDevelopmentOfVaccines #VaccineVectors #CellularAndMolecularImmuneResponses #BreakthroughsInImmunotherapeutics #VaccineSafety #PeertechzPublications #EfficacyAndClinicalTrials #ImmunityToInfection #Immunomodulation #CaseReports #ClassicalImmunology #ClinicalImmunology #ComputationalImmunology #DiagnosticImmunology #EvolutionaryImmunology #Immunotherapy #SystemsImmunology #CancerImmunology #TesticularImmunology

Save the Date! 🚀 Flanders Vaccine is thrilled to invite you to a unique symposium on groundbreaking research and innovations in vaccine delivery and immune response!💉 📅 Date: September 17th 📍 Location: Vestar, Antwerp Join us for this pivotal event where researchers and industry experts will come together to discuss innovative approaches and critical considerations in vaccine formulation and administration. 🔬 Key Discussions Include: 🌟 Impact of various vaccine formulations and delivery routes on immune responses. 🌟 Tailoring administration routes like intradermal, mucosal, intramuscular, and more to achieve optimal outcomes. 🌟 Strategic selection of delivery methods based on infection routes of target pathogens. 🌟 Importance of adjuvant selection and advanced technologies like lipid nanoparticles in vaccine formulation. Don’t miss this unique opportunity to engage with cutting-edge research and contribute to the evolving landscape of vaccine development and immune response optimization. 🗓️ Mark your calendars and stay tuned for more details! 🗓️ #VaccineSymposium #FlandersVaccine #VaccineInnovation #ImmuneResponse #VaccineDevelopment #SaveTheDate